| Nexavar® (sorafenib) tablets |
 |
Liver Cancer: First line, single agent
|
First line, doxorubicin +/-
|
Post-TACE (Japan)
|
|
Kidney Cancer: Advanced kidney cancer
|
Adjuvant, vs sunitinib vs placebo (US)
|
Adjuvant, vs placebo (EU)
|
Dose escalation
|
Combinations
|
|
Non-Small Cell Lung Cancer: First line, gemcitabine/cisplatin +/-
|
Second/Third line (ECOG)
|
Second line, Alimta +/-
|
First line, carboplatin/Alimta +/-
|
|
Melanoma: First line, carboplatin/paclitaxel +/-
|
Multiple lines, temozolomide
|
|
Breast Cancer: First line, paclitaxel +/-
|
First/second line, capecitabine +/-
|
First/second line, gemcitabine +/-
|
First line, docetaxel or letrozole +/-
|
First/second line, aromatase inhibitors +/-
|
|
|
| Cell Cycle Kinase Inhibitor |
 |
|
Last updated: February 2008
